| Co-Chairs |
|
George W. Sledge, Jr., MD
Ballve-Lantero Professor
of Oncology and Pathology
Co-Director, Breast Cancer Program
Indiana University Cancer Center
Co-Chair, Breast Committee,
The Eastern Oncology Cooperative Group
(ECOG)
|
|
Dennis J. Slamon, MD, PhD
Chief, Division of Hematology-Oncology
Professor and Executive Vice Chair, Department of Medicine
Director for Clinical Research
Jonsson Comprehensive Cancer Center
Director, Revlon/UCLA Women's Health Research and Cancer Research Programs
University of California at Los Angeles School of Medicine
Los Angeles, CA
|
| |
|
|
|
|
|
CME-Accredited Webcasts, Presentation and Audio Downloads, and
i-Tunes Podcast Downloads
19 didactic presentations, 7 panel discussions, 5 case studies, and 8 Point-Counterpoint debates from the live course
"Second Annual Symposium on Personalized Therapies for Breast Cancer"
held in Miami, FL on January 24-25, 2009
|
You may participate in any or all of the sessions for CME credit or a Certificate of Attendance after you review the required ACCME (Accreditation Council on Continuing Medical Education) information on this page.
|
|
Menu
|
|
Overview of This CME-Accredited Educational Activity
Your Options for Methods of Participation are:
- View and/or listen to any of the sessions (listed below) via an Adobe Flash Webcast
- Download any slides as Adobe Acrobat files
- Download any audio only as MP3s or Podcasts
- Request a DVD-ROM of all sessions
|
There are 19 didactic presentations, 7 interactive panel discussions, 5 case studies, and 8 Point-Counterpoint debates between the faculty and audience with both clinical cases and audience questions. Each of these sessions is approximately 20 minutes in length. Sessions can be individually reviewed for credit. You can participate in as few or as many as you desire.
CME-Accredited Educational Activity Dates and Time to Complete
Date of release: March 9, 2009
Date expires (CME credit will not be avaliable): March 9, 2010
Average time to complete each individual session: 20 minutes
Time to complete entire activity: 13 hours
Overview
For the treatment of breast cancer, the practice of medicine and patient care is now
evolving from what has traditionally been a general approach with standardized therapies,
to a more personalized therapeutic approach with the selection of therapies specific to
patients and their malignancies. The ability to accomplish this is based upon the increasing
ability of clinicians to apply the newest and ever expanding clinical, scientific, genetic,
and other molecular data used as predictive and prognostic biomarkers for improved
therapies and patient outcomes, and a minimization of treatment-induced toxicities. The
objective of this Internet CME activity is to further these efforts with an enhanced activity containing significant new content,
many new expert faculty and a more interactive audience-faculty format from last
year’s program. All Sessions contain at least one major patient case study with multiple choice
treatment care options that the live audience selected via the Audience Response System
(ARS), and at least one Point-CounterPoint debate whereby the audience voted via
ARS. Most of the didactic presentations include at least one brief patient case study
or, one clinical question that the audience voted upon via ARS. And, finally each Session
concludes with a 15-minute “consensus” period where each of the following three questions
were asked of the Session’s faculty and audience via ARS regarding the particular
Session’s content to help ensure that this newly presented information can be applied to
clinical practice today: 1) Is this a new standard of care? 2) Should it be discussed with
your patients? and 3) How can you use it today in your practice?
The content of this Internet CME activity has been modified to reflect the newest clinical and scientific information regarding
further personalization of therapies. These are addressed in the following seven
Sessions. Session 1, “Personalizing Therapies for the Prevention of Breast Cancer,”
addresses: predicting who may develop breast cancer; the use of genetic testing for
breast cancer prevention; and the clinical application of SERMS and other strategies to
prevent breast cancer. Session 2, “Diagnosis and Molecular Classifications of Breast
Cancer for Personalizing Therapies,” reviews several types of molecular tests and their
clinical applications, including multi-gene assays and gene expression profiling to help
personalize the selection of therapy for breast cancer patients via predictive and prognostic
factors. Session 3, “Personalized Approaches to Early Therapy of Breast Cancer,”
addresses the latest data on the personalizing of radiation therapy, surgical therapy, and
local-regional control, including approaches with neo-adjuvant chemotherapy. Session 4, “Clinical Applications of Personalized Therapies for HER2+ Breast Cancers,” reviews the
most current clinical and scientific data on new applications of anti-HER2 strategies,
and advances in personalizing clinical anti-HER2 strategies in both the adjuvant and
metastatic breast cancer settings. “Lunch with the Professors” follows Sessions 4
and 6. Session 5, “Clinical Applications of Personalized Therapies for ER+
Breast Cancers,” addresses many new topics including the personalizing or predicting
of response to adjuvant endocrine therapy, overcoming resistance to endocrine therapy,
the use of SNPs to help personalize the selection of endocrine therapies, and the issue
of how elderly patients with breast cancer should be treated. Session 6, “Clinical
Applications of Personalized Therapies for Triple-Negative Disease,” will provide an
update on the pathology and biology of this sub-type, and review strategies to personalize
therapies with anti-angiogenic and chemotherapeutic approaches. Session 7,
“New Developments in the Treatment of Bone Metastases, and the Management of
Bone Health and Bone Integrity.” This Session is an entirely new session for this year’s
activity because of the significant potential for adjuvant therapeutic applications of
drugs that traditionally treated bone metastases, and, the emergence of newer,
“targeted” biological approaches for the treatment of bone metastases, and the
management of bone integrity and bone health.
Physician Practice Gap Summary (formerly Educational Needs Summary)
Breast cancer is the most commonly diagnosed cancer in women in the United States.
In 2007, an estimated 180,510 new cases were diagnosed and 40,910 deaths were
attributed to breast cancer. Approximately 30% of women diagnosed with early breast
cancer will eventually die of their disease. Metastatic breast cancer is incurable and often
difficult to treat. Few patients will be long-term survivors. As more is learned about the
molecular biology of breast cancer and newer therapies, the evolving personalized approach
to treating this malignancy should help physicians improve clinical outcomes and
decrease the mortality rate.
Breast cancer risk can today be further characterized using genetic markers. Molecular
biology techniques such as genome-wide linkage analysis and positional cloning have
led to the identification of and tests for breast cancer susceptibility genes such as BRCA1
and BRCA2. Women with BRCA1 or BRCA2 mutations have a lifetime risk of developing
breast cancer of between 50% and 80%. The diagnosis and molecular classifications of
breast cancer sub types continue to advance with the commercial availability of more
tests, and further developments in molecular testing emerging. All of these tests need to
be reviewed, and their specific clinical applications carefully understood. Personalizing
radiation therapy, surgical therapy, and local-regional control, including approaches with
neo-adjuvant chemotherapy, are also areas of breast cancer treatment where physicians
will benefit from the newest information on these topics.
HER2 remains both a vitally important target for some breast cancer therapies, and, a
biomarker for poor prognosis. The identification and understanding of novel methodologies
used as prognostic factors, or predictive factors for therapies against HER2 is an
ongoing need. And the expanding clinical role of anti-HER2 therapy warrants a thorough
review and update.
Because estrogen plays a key role in the growth and proliferation in some breast
cancers, endocrine therapy is standard treatment in post-menopausal women who are
hormone receptor-positive. One of the most challenging aspects of using endocrine
therapy is personalizing therapy---determining which patients should receive which
therapy and how long should endocrine therapy be used in a specific patient. Another is
the challenge in treating patients who may have resistance to endocrine treatment. The
use of molecular biomarkers, predictive factors and gene expression profile assays in a
personalized approach to breast cancer treatment needs to be further reviewed.
Triple-negative breast cancer is a sub type of breast malignancy that remains very
challenging for physicians. With increased understanding of the biology of triple-negative
tumors, improvements in clinical outcome may be possible. Because patients with this
breast cancer classification do not have good prognosis, an in depth review of how these
patients can be optimally treated utilizing the latest results of clinical trials is warranted.
The bone is the most common site of distant metastasis in breast cancer. This past year,
new clinical data has emerged with the usage of bisphosphonates to treat bone metastases
resulting in an adjuvant treatment of breast cancer itself. And there are several therapeutics
in late-stage clinical development to further reduce the risk of skeletal related
events. These include strategies to inhibit the RANK Ligand, TGF-beta, cathepsin-K and
src. A review of these new strategies and a discussion on how to personalize therapies
using these strategies needs to be discussed.
The following is list of all sessions
Session 1: Personalizing therapies for the prevention
of breast cancer
Chair: Mark Pegram, MD |
| 1a. |
Predicting who will develop breast cancer
Malcom C. Pike, PhD
|
| 1b. |
The clinical application of
genetic testing for breast
cancer prevention
Jeffrey N. Weitzel, MD
|
| 1c. |
Drug prevention strategies
using SERMS and other
agents for patients at high risk
of developing breast cancer
Powel H. Brown, MD, PhD
|
| 1d. |
Point-Counterpoint: All patients
at high risk for developing
breast cancer should receive
SERMS prophylactically
Powel H. Brown, MD, PhD vs. Jeffrey N. Weitzel, MD
|
| 1e. |
Session 1 Case Study
Mark Pegram, MD
|
| 1f. |
Panel Discussion, Q & A, and Consensus on the Status of the Data Presented in this Session
Mark Pegram, MD, Powel H. Brown, MD, PhD, Malcom C. Pike, PhD, and Jeffrey N. Weitzel, MD
|
Session 2: Diagnosis and molecular clasifications of
breast cancer for personalizing therapies
Chair: Harold J. Burstein, MD, PhD |
|
2a. |
In which patients with breast cancer are gene expression arrays beneficial as prognostic markers today?
Charles M. Perou, PhD |
|
2b.
|
Response to Neoadjuvant Chemotherapy: what we can predict to do and what we cannot
Lajos Pusztai, MD, DPhil
|
|
2c.
|
Point-Counterpoint: Use the 70-gene microarray assay versus the 21-gene panel assay for testing ER+, node-negative breast cancer
Lajos Pusztai, MD, DPhil vs. George W. Sledge, Jr., MD
|
|
2d.
|
Session 2 Case Study
Harold J. Burstein, MD, PhD
|
|
2e.
|
Panel Discussion, Q & A, and Consensus on the Status of the Data Presented in this Session
Harold J. Burstein, MD, PhD, Charles M. Perou, PhD, Lajos Pusztai, MD, DPhil, and George W. Sledge, Jr., MD
|
Session 3: Personalized aproaches to early therapy
of breast cancer
Chair: Lori J. Pierce, MD |
|
3a.
|
Individualizing local-regional control with neo-adjuvant chemotherapy
Eleftherios P. Mamounas, MD, MPH, FACS
|
|
3b.
|
Personalizing radiation therapy for breast cancer
Lori J. Pierce, MD
|
|
3c.
|
Personalizing surgical therapy for breast cancer
Kelly K. Hunt, MD, FACS
|
|
3d.
|
Point-Counterpoint: T[a taxane]+ C[a platinum]+ H[an anti-HER2] should replace anthracycline-based therapies for adjuvant therapy of HER2-positive breast cancer
Dennis J. Slamon, MD, PhD vs. Harold J. Burstein, MD, PhD
|
|
3e.
|
Panel Discussion, Q & A, and Consensus on the Status of the Data Presented in this Session
Lori J. Pierce, MD, Harold J. Burstein, MD, PhD, Kelly K. Hunt, MD, FACS, Eleftherios P. Mamounas, MD, MPH, FACS, and Dennis J. Slamon, MD, PhD
|
Session 4: Clinical applications of personalized therapies for HER2+ breast cancers
Chair: Dennis J. Slamon, MD, PhD
|
|
4a.
|
Personalized approaches to selecting targeted therapies and chemotherapies for metastatic HER2+ breast cancer patients
Dennis J. Slamon, MD, PhD
|
|
4b.
|
Predictors of response and personalized approaches for selecting patients with HER2+ breast cancer for adjuvant and neo-adjuvant anti-HER2 therapy
Carlos L. Arteaga, MD
|
|
4c.
|
The relationship between HER2 expression and response to taxane-based therapies
Hyman Muss, MD
|
|
4d.
|
Point-Counterpoint: Adjuvant anti-HER2 therapy should be considered for HER2-negative patients?
Hyman Muss, MD vs. Michael F. Press, MD, PhD
|
|
4e.
|
Point-Counterpoint: A taxane plus an alkylating agent should replace anthracycline-based therapies for adjuvant therapy of HER2-negative breast cancer
Hyman Muss, MD vs. Harold J. Burstein, MD, PhD
|
|
4f.
|
Panel Discussion, Q & A, and Consensus on the Status of the Data Presented in this Session
Dennis J. Slamon, MD, PhD, Carlos L. Arteaga, MD, Harold J. Burstein, MD, PhD, Hyman Muss, MD, and Michael F. Press, MD, PhD
|
Session 5: Clinical applications of personalized therapies for ER+ breast cancers
Chair: Edith A. Perez, MD
|
|
5a.
|
What are the molecular predictors of response to adjuvant endocrine therapy?
W. Fraser Symmans, MD
|
|
5b.
|
Are there personalized strategies for overcoming resistance to endocrine therapy?
V. Craig Jordan, OBE, PhD, DSc
|
|
5c.
|
Personalized approaches to treating patients with ER+ breast cancer using single nucleotide polymorphisms (SNPs)
David Flockhart, MD, PhD
|
|
5d.
|
Point-Counterpoint: Systemic therapy for the elderly should be identical to that for younger patients
Edith A. Perez, MD vs. George W. Sledge, Jr., MD
|
|
5e.
|
Session 5 Case Study
Edith A. Perez, MD
|
|
5f.
|
Panel Discussion, Q & A, and Consensus on the Status of the Data Presented in this Session
Edith A. Perez, MD, David Flockhart, MD, PhD, V. Craig Jordan, OBE, PhD, DSc, George W. Sledge, Jr., MD, and W. Fraser Symmans, MD
|
Session 6: Clinical applications of personalized therapies for triple-negative disease
Co-Chairs: Lisa A. Carey, MD and Clifford A. Hudis, MD
|
|
6a.
|
Pathology and molecular classification of Triple-Negative Carcinoma
Edi Brogi, MD, PhD
|
|
6b.
|
Personalizing breast cancer therapies using anti-angiogenic strategies
George W. Sledge, Jr., MD
|
|
6c.
|
Therapeutic individualization with specific chemotherapeutic agents
Lisa A. Carey, MD
|
|
6d.
|
Point-Counterpoint: All triple-negative patients should receive platinum-based adjuvant therapy
Lisa A. Carey, MD vs. Clifford A. Hudis, MD
|
|
6e.
|
Session 6 Case Studies
Lisa A. Carey, MD and Clifford A. Hudis, MD
|
|
6f.
|
Panel Discussion, Q & A, and Consensus on the Status of the Data Presented in this Session
Lisa A. Carey, MD, Clifford A. Hudis, MD, Edi Brogi, MD, PhD, and George W. Sledge, Jr., MD
|
Session 7: New developments in the treatment of bone metastases, and the management of bone health and bone integrity
Chair: Allan Lipton, MD
|
|
7a.
|
Drugs treating bone metastases: are they supportive care agents, therapeutics, or both?
Katherine Weilbaecher, MD
|
|
7b.
|
Newer clinical strategies for treating bone metastases
Allan Lipton, MD
|
|
7c.
|
Point-Counterpoint: Drugs treating bone metastases should be offered to patients as an option for adjuvant therapy of breast cancer
Allan Lipton, MD vs. Katherine Weilbaecher, MD
|
|
7d.
|
Session 7 Case Study
Allan Lipton, MD
|
|
7e.
|
Panel Discussion, Q & A, and Consensus on the Status of the Data Presented in this Session
Allan Lipton, MD and Katherine Weilbaecher, MD
|
|
|
|
Educational Objectives
At the conclusion of all of these enduring materials, you should be able to:
- Evaluate the personalized therapeutic approach for the prevention of breast cancer and to help patients prevent the development of breast cancer or breast cancer recurrence.
- Evaluate the effect of new technologies on the classification and staging of breast cancer and to utilize this new information in the planning of breast cancer treatment.
- Devise strategies to improve local-regional control of breast cancer through a personalized approach to breast cancer treatment.
- Assess clinical data regarding the selection of adjuvant treatments of breast cancer and devise treatment strategies utilizing a personalized approach to therapy in patients with early-stage breast cancer to prevent disease recurrence.
- Analyze the data supporting the use of chemotherapy, targeted therapy, endocrine therapy and radiation therapy in the personalized treatment of patients with advanced disease.
- Understand new clinical data regarding new approaches to maintaining bone health and to utilize new approaches to prevent skeletal-related events in patients with early-stage breast cancer and in patients with metastatic disease.
- Evaluate new approaches in identifying patients with triple-negative disease and utilize a personalized approach in the selection of therapies for patients with triple-negative breast cancer.
Target Audience
This activity is designed to meet the educational needs of physicians who are involved with the diagnosis and treatment of patients with breast cancer. This includes medical oncologists and hematologist/oncologists, radiation oncologists, surgical oncologists and pathologists. There are neither prerequisites nor relevant system barriers to these activities.
CME Accreditation & Credit Designation
The Oncology Learning Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Oncology Learning Center designates this educational activity for a maximum of 13 AMA PRA Category 1
Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
CME Certificate or Certificate of Participation
The relevant section(s) of the Evaluation Form pertaining to the session(s) of the enduring materials you have viewed or listened to, and the Request for Credit Form must be completed and submitted to the Oncology Learning Center following your participation in the enduring material educational activity to obtain CME credit. Physicians and other participants will be able to print their certificates after they complete these Forms.
Disclosure of Conflicts of Interest
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by the Oncology Learning Center must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, and planning committee members participating in an OLC-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity. |
|
Faculty Disclosures
It is the policy of The Oncology Learning Center™, Inc. (OLC) to ensure that all of its educational activities and materials are of the highest quality, and are balanced, objective, independent, free of commercial bias, and planned and developed with scientific rigor with strict adherence to all Accreditation Council for Continuing Medical Education (ACCME) rules and policies. The OLC evaluates all content, faculty and faculty disclosures for any potential conflicts of interest. Should any conflicts of interest be identified these conflicts are resolved in advance of the educational activity by independent peer reviewers who are experts in the subjects of the educational activity.
All faculty and OLC staff participating in the content, planning or implementation of an educational CME activity are required to disclose to the audience of the educational activity any relevant financial relationships or interests and to assist in the resolution of any conflict of interest that may arise from the relationship(s) or interest(s). It is also the policy of the OLC to require all faculty presenters to make a meaningful disclosure to the audience of their discussions of unlabeled or FDA unapproved drugs, products, tests or devices. This information will be available as part of the educational activity and related material.
The following faculty and OLC staff have reported real or potential relevant conflicts of interest and these conflicts have been resolved, prior to this educational activity through a peer-review process by two medical oncologists who have had no affiliation with this educational activity other than the peer review process. This is documented on this page immediately following the financial disclosures below.
|
Carlos L. Arteaga, MD
Consultant: BMS, InNexus, OSI Pharm, Monogram, AstraZeneca
Contracted Research: Lilly, Merck, Monogram Biosciences
Edi Brogi, MD, PhD
I have no real or apparent conflicts of interest to report.
Powel H. Brown, MD, PhD
Other: AstraZeneca, Lilly Pharmaceutical
Howard Burstein, MD, PhD
I have no real or apparent conflicts of interest to report.
Lisa A. Carey, MD
Contracted Research: Genentech, BiogenIdec, BMS, GSK, Pfizer
David Flockhart, MD, PhD
Consultant: Medco HC, Labcorp, Inc.
I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.
Clifford A. Hudis, MD
Consultant: Amgen, BMS, Genentech, GSK, Novartis, Pfizer, Sanofi-Aventis
Contracted Research: AstraZeneca, BMS, Onyx Pharmaceuticals
I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.
Kelly K. Hunt, MD, FACS
I have no real or apparent conflicts of interest to report.
V. Craig Jordan, OBE, PhD, DSc
I have no real or apparent conflicts of interest to report.
Allan Lipton, MD
Consultant: Amgen, Novartis, Merck, GSK, Incyte, Acceleron, Gtx, Inc., AstraZeneca
Fees for Non-CME Services Received Directly from Commercial Interest: Amgen, Novartis, Genentech
Contracted Research: Monogram Biosciences, Novartis, Oncogene Sciences
Eleftherios P. Mamounas, MD, MPH, FACS
Consultant: Roche, Genentech, Sanofi-Aventis, Genomic Health, Agendia, Pfizer
Fees for Non-CME Services Received Directly from Commercial Interest: Genentech, Sanofi-Aventis, Genomic Health
I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.
|
Hyman Muss, MD
Consultant: Pfizer, Genentech, Amgen, Roche, BMS, Tragera
Contracted Research: AstraZeneca, Pfizer, GSK, Genentech, Novartis
I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.
Edith A. Perez, MD
I have no real or apparent conflicts of interest to report.
Charles M. Perou, PhD
Consultant: Eli Lilly, Roche, PharmaMar
Contracted Research: Eli Lilly, BMS, Roche
Ownership Interest: University of Genomics
Lori J. Pierce, MD
I have no real or apparent conflicts of interest to report.
Malcolm C. Pike, PhD
I have no real or apparent conflicts of interest to report.
Michael F. Press, MD, PhD
Consultant: GSK
Contracted Research: Genentech, GSK
Lajos Pusztai, MD, DPhil
Ownership Interest: Nuvera Biosciences
George W. Sledge, Jr., MD
Consultant: Genomic Health, GSK, Genentech
Contracted Research: Eli Lilly, Sanofi-Aventis
W. Fraser Symmans, MD
Consultant: Agendia
Ownership Interest: Nuvera Biosciences
Katherine Weilbaecher, MD
Fees for Non-CME Services Received Directly from Commercial Interest: Novartis Oncology
I have no real or apparent conflicts of interest to report
Jeffrey N. Weitzel, MD
I have no real or apparent conflicts of interest to report.
Oncology Learning Center staff
We have no real or apparent conflicts of interest to report.
|
Faculty Affiliations
Carlos L. Arteaga, MD
Vice Chancellor’s Professor of Breast Cancer Research,
Professor of Medicine and
Professor of Cancer Biology
Vanderbilt-Ingram Cancer Center
Nashville, TN
|
|
Edith A. Perez, MD
Professor of Medicine
Director, Clinical Research
Mayo Clinic
Jacksonville, FL
Chair, Breast Committee,
The North Central Cancer Treatment Group (NCCTG)
|
Edi Brogi, MD, PhD
Associate Professor of Clinical Pathology
and Laboratory Medicine
Weill Medical College of Cornell University
Associate Attending Pathologist
Memorial Sloan-Kettering Cancer Center
New York, NY
|
|
Charles M. Perou, PhD
Associate Professsor
Department of Genetics
University of North Carolina
Chapel Hill, NC
|
Powel H. Brown, MD, PhD
Professor of Medicine,
Baylor College of Medicine
Associate Director of Cancer Prevention,
Director of Cancer Prevention and
Population Sciences Program,
Dan L. Duncan Cancer Center
Associate Director of Research,
Breast Center
Baylor College of Medicine
Houston, TX
|
|
Lori J. Pierce, MD
Vice Provost for Academic and Faculty Affairs
Professor, Department of Radiation Oncology
University of Michigan
Ann Arbor, MI
|
Harold J. Burstein, MD, PhD
Professor of Medicine
Division of Medical Oncology
Dana-Farber Cancer Institute
Harvard Medical School
|
|
Malcolm C. Pike, PhD
Professor and Acting Chair
Flora L. Thornton Professor
USC Norris Cancer Center
Los Angeles, CA
|
Lisa A. Carey, MD
Medical Director,
UNC Breast Cancer
University of North Carolina
Lineberger Comprehensive Cancer Center
|
|
Michael F. Press, MD, PhD
Holder of Harold E. Lee Chair in Cancer Research
Professor of Pathology
Keck School of Medicine
USC Norris Cancer Center
Los Angeles, CA
|
David Flockhart, MD, PhD
Director, Division of Endocrinology and Pharmacology
Indiana University School of Medicine
|
|
Lajos Pusztai MD, DPhil
Associate Professor of Medicine
Department of Breast Medical Oncology
The University of Texas M. D. Anderson Cancer Center
Houston, TX
|
Clifford A. Hudis, MD
Chief, Breast Cancer Medicine Service
Memorial-Sloan Kettering Cancer Center
New York, NY
Co-Chair, Breast Committee,
|
|
Daniel Silver, MD, PhD
Instructor, Department of Medicine
Harvard Medical School
Instructor, Cancer Biology
Dana-Farber Cancer Institute
Boston, MA
|
Kelly K. Hunt, MD, FACS
Professor of Surgery
Chief, Surgical Breast Section
Department of Surgical Oncology
The University of Texas M. D. Anderson Cancer Center
|
|
Dennis J. Slamon, MD, PhD
Chief, Division of Hematology-Oncology
Professor and Executive Vice Chair, Department of Medicine
Director for Clinical Research
Jonsson Comprehensive Cancer Center
Director, Revlon/UCLA Women’s Health Research and
Cancer Research Programs
University of California at Los Angeles School of Medicine
Los Angeles, CA
|
V. Craig Jordan, OBE, PhD, DSc
Senior Member Medical Science Division
Vice President and Scientific Director for Medical Science
Alfred G Knudson Jr. Chair in Cancer Research
Fox Chase Cancer Center
|
|
George W. Sledge, Jr., MD
Ballvé-Lantero Professor of Oncology and Pathology
Co-Director, Breast Cancer Program
Indiana University Cancer Center
Indianapolis, IN
Co-Chair, Breast Committee,
The Eastern Oncology Cooperative Group (ECOG)
|
Allan Lipton , MD
Professor of Medicine and Oncology
M. S. Hershey Medical Center of the
Pennsylvania State University
Hershey, PA
|
|
W. Fraser Symmans, MD
Professor of Pathology
The University of Texas M. D. Anderson Cancer Center
Houston, TX
|
Eleftherios P. Mamounas, MD, MPH, FACS
Professor of Surgery
Northeastern Ohio Universities College of Medicine
Medical Director, Aultman Cancer Center
Chairman, Breast Committee National Surgical Adjuvant
Bowel Project (NSABP)
|
|
Katherine Weilbaecher, MD
Associate Professor of Medicine
Washington University School of Medicine
Division of Molecular Oncology
St. Louis, MO
|
Hyman Muss, MD
Professor of Medicine
Vermont Cancer Center
Fletcher Allen Health Care
Burlington, VT
|
|
Jeffrey N. Weitzel, MD
Professor of Medicine
Medical Oncology
Director of Clinical Cancer Genetics and
Cancer Screening and Prevention Program
City of Hope Comprehensive Cancer Center
Duarte, CA
|
Mark Pegram, MD
Professor of Medicine and Oncology
University of Miami Cancer Center
Miami, FL
|
|
|
|
Peer Review Process of Conflicts of Interest
This educational activity has been independently peer-reviewed.
Disclosure of Unlabeled Uses
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration (FDA). For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product or consult the Physicians’ Desk Reference.
The Oncology Learning Center (OLC) does not recommend the use of any agent outside of the FDA labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the OLC. Please refer to the official FDA prescribing information for each product for discussion of approved indicated, contraindications, and warnings.
Acknowledgement of Supporters
|
